Unlock stock picks and a broker-level newsfeed that powers Wall Street.
NasdaqGM - Nasdaq Real Time Price USD

TransMedics Group, Inc. (TMDX)

Compare
68.58
-1.86
(-2.64%)
At close: March 28 at 4:00:00 PM EDT
68.20
-0.38
(-0.55%)
After hours: March 28 at 7:56:52 PM EDT
Loading Chart for TMDX
  • Previous Close 70.44
  • Open 69.80
  • Bid 49.83 x 100
  • Ask 87.18 x 100
  • Day's Range 67.75 - 70.42
  • 52 Week Range 55.00 - 177.37
  • Volume 612,497
  • Avg. Volume 1,743,381
  • Market Cap (intraday) 2.309B
  • Beta (5Y Monthly) 2.12
  • PE Ratio (TTM) 64.09
  • EPS (TTM) 1.07
  • Earnings Date Apr 28, 2025 - May 2, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 102.86

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

www.transmedics.com

728

Full Time Employees

December 31

Fiscal Year Ends

Recent News: TMDX

View More

Performance Overview: TMDX

Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

TMDX
9.99%
S&P 500 (^GSPC)
5.11%

1-Year Return

TMDX
7.25%
S&P 500 (^GSPC)
6.22%

3-Year Return

TMDX
173.99%
S&P 500 (^GSPC)
21.97%

5-Year Return

TMDX
483.16%
S&P 500 (^GSPC)
119.59%

Compare To: TMDX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: TMDX

View More

Valuation Measures

Annual
As of 3/28/2025
  • Market Cap

    2.31B

  • Enterprise Value

    2.49B

  • Trailing P/E

    64.09

  • Forward P/E

    45.25

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.47

  • Price/Book (mrq)

    10.10

  • Enterprise Value/Revenue

    5.64

  • Enterprise Value/EBITDA

    35.60

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    8.03%

  • Return on Assets (ttm)

    3.10%

  • Return on Equity (ttm)

    19.39%

  • Revenue (ttm)

    441.54M

  • Net Income Avi to Common (ttm)

    35.46M

  • Diluted EPS (ttm)

    1.07

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    336.65M

  • Total Debt/Equity (mrq)

    226.72%

  • Levered Free Cash Flow (ttm)

    -102.77M

Research Analysis: TMDX

View More

Company Insights: TMDX

Research Reports: TMDX

View More

People Also Watch